Journal of Capital Medical University ›› 2018, Vol. 39 ›› Issue (6): 937-944.doi: 10.3969/j.issn.1006-7795.2018.06.025

Previous Articles     Next Articles

Gene mutations and clinical phenotypes in three families with short stature and brachydactyly and review of literature

Hu Xuyun1, Wu Di2, Li Mengting3, Chen Jiajia2, Li Xiaoqiao2, Su Chang2, Chen Shaoke3, Shen Yiping3,4,5, Gong Chunxiu2   

  1. 1. Beijing Key Laboratory for Genetics of Birth Defects, MOE Key Laboratory of Major Diseases in Children, Center for Medical Genetics, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China;
    2. Beijing Key Laboratory for Genetics of Birth Defects, MOE Key Laboratory of Major Diseases in Children, Department of Endocrinology, Genetics and Metabolism, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China;
    3. Genetic and Metabolic Central Laboratory, Guangxi Maternal and Child Health Hospital, Nanning 530003, China;
    4. Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China;
    5. Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston 02115, USA
  • Received:2018-10-22 Online:2018-11-21 Published:2018-12-19
  • Supported by:
    This study was supported by National Natural Science Foundation of China (81570220).

Abstract: Objective To evaluate the clinical phenotypes and genetic variations of three Chinese patients with familial short stature and brachydactyly. Methods Three patients with short stature and brachydactyly from Beijing Children's Hospital were molecularly confirmed with specific subtypes of brachydactyly via next generation sequencing. Their parents were also sequenced for segregation information. Growth hormone therapy was initiated after diagnosis. Results c.283_285delGAG/p.E95del in IHH, c.2625dupC/p.T876fs*20 in ROR2 or c.413delA/p.K138fs*11 in PTHLH was identified in every family, thus the patients from these three families were diagnosed as brachydactyly A1, brachydactyly B1 and brachydactyly E2, respectively. After growth hormone therapy, the heights of three patients were significantly improved (+0.99 SD,+0.64 SD and+2.69 SD respectively). Conclusion The genetic heterogeneity of brachydactyly combined with short stature can be uncovered by next generation sequencing. In this study, we reported two novel pathogenic variants in ROR2 and PTHLH genes, as well a previously reported IHH hotspot mutation which was identified in Chinese population for the first time. Growth hormone therapy was effective for all three patients.

Key words: short, stature brachydactyly, genetic diagnosis, next generation sequencing, growth hormone therapy

CLC Number: